联合VEGF受体抑制剂和血管紧张素-(1-7)治疗肾细胞癌。

IF 2.6 Q3 ONCOLOGY

Molecular and Cellular Oncology Pub Date : 2021-06-12 eCollection Date: 2021-01-01 DOI:10.1080/23723556.2021.1918529

Thomas Walther, Prateek Khanna, Rupal S Bhatt

引用次数: 1

摘要

大多数转移性肾癌患者不可避免地对血管内皮生长因子受体酪氨酸激酶抑制剂产生耐药性。我们最近的研究结果表明，添加血管紧张素-(1-7)肽可能是延迟这种耐药性的潜在治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Combining VEGF receptor inhibitors and angiotensin-(1-7) to target renal cell carcinoma.

Resistance to tyrosine kinase inhibitors of the vascular endothelial growth factor receptor inevitably develops in most patients with metastatic kidney cancer. Our recent findings demonstrate that addition of angiotensin-(1-7) peptide can be a potential therapy that delays such resistance.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Molecular and Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.